Companies/EU/OSE

OSE IMMUNOTHERAPEUTICS

Income flow

Annual
OSE ANNUAL Income StatementPeriod 2025-12-31Source ANNUAL
Net salesEUR 3M-96% Y/YRevenueEUR 3M-96% Y/Y

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).24.7MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).17.3M